Seattle Genetics' Antibody Drug Conjugate Tech Prominent at ASCO Meeting

Seattle Genetics, the company that pioneered the antibody-drug conjugate (ADC) platform in Adcetris, the Hodgkin's lymphoma treatment, has data presented from a handful of collaborator programs at the American Society of Clinical Oncology's (ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL.

Preliminary data from ongoing clinical trials were presented in the treatment of the likes of prostate cancer, glioblastoma, and non-small cell lung cancer.

ADCs Against NHLs

Others included prelim results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients diagnosed with relapsed or refractory non-Hodgkin lymphoma.

Both polatuzumab vedotin (anti-CD79b) and pinatuzumab vedotin (anti-CD22) are ADCs being developed by Genentech. They consist of anti-CD79b or anti-CD22 monoclonal antibody conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) using Seattle Genetics’ ADC technology.

Preliminary results from an ongoing phase 2 clinical trial were reported evaluating the activity and safety of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in 59 and 63 patients, respectively, with relapsed or refractory non-Hodgkin lymphoma (NHL).

Both polatuzumab vedotin and pinatuzumab vedotin demonstrated antitumor activity with similar and generally acceptable safety profiles. Durable responses were observed in both diffuse large b-cell lymphoma (DLBCL) and follicular lymphoma. This included patients refractory to rituximab and/or their most recent therapy. Treatment with polatuzumab vedotin plus rituximab demonstrated an objective response of 56 percent (22 of 39 patients) in DLBCL and 70 percent (14 of 20 patients) in follicular lymphoma. Treatment with pinatuzumab vedotin plus rituximab demonstrated an objective response of 57 percent (24 of 42 patients) in DLBCL and 62 percent (13 of 21 patients) in follicular lymphoma.

"Researchers at Seattle Genetics have identified and optimized novel components that are fundamental to creating antibody-drug conjugates, including potent cell-killing agents and conditionally stable linker systems," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. "Our collaborators are making great progress in advancing novel ADC candidates as evidenced by the encouraging data presentations at ASCO. Seattle Genetics continues to lead the field in developing ADC candidates, which demonstrate the therapeutic potential of our technology broadly through both our proprietary and collaborator programs."

Source: MarketWatch

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap